NCS105360 | 95953-57-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: NCS105360
• 英文别名: 1,3-bis-(benzo[1,3]dioxol-5-yl-acetyl)-indole；1,3-Di-<3,4-methylendioxyphenylacetyl>-indol；2-(1,3-Benzodioxol-5-yl)-1-[1-[2-(1,3-benzodioxol-5-yl)acetyl]indol-3-yl]ethanone
• CAS: 95953-57-4
• 化学式: C₂₆H₁₉NO₆
• 分子量: 441.44
• InChiKey: NFSRNVOYRDSTCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  76
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  NCS105360 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-benzo[1,3]dioxol-5-yl-1-indol-3-yl-ethanone
  参考文献：
  名称：

  Biindolyls. III. Substituted 2,3'-Biindolyls from 3-Arylacetylindoles^1,2

  摘要：

  DOI：

  10.1021/jo01030a515
• 作为产物：
  描述：

  吲哚 、 苯并[1,3]二氧代-5-乙酰氯 生成 NCS105360
  参考文献：
  名称：

  Biindolyls. III. Substituted 2,3'-Biindolyls from 3-Arylacetylindoles^1,2

  摘要：

  DOI：

  10.1021/jo01030a515

文献信息

• Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
  申请人：Jorcyk Cheryl

  公开号：US10286070B2

  公开（公告）日：2019-05-14

  A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.

  提供了一种治疗癌症或转移瘤的方法，该方法涉及对受试者施用至少一种Oncostatin M（OSM）拮抗剂，其中受试者已被诊断患有癌症。提供了一种 OSM 拮抗剂（如小分子药物）以及一种抗 OSM 抗体、一种抗 OSM 合酶和一种 OSM mRNA 拮抗剂。研究发现，OSM拮抗剂可抑制或防止几种癌症类型的肿瘤细胞脱落、增殖和转移。
• ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS
  申请人：Jorcyk Cheryl

  公开号：US20150093391A1

  公开（公告）日：2015-04-02

  A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.
• US9550828B2
  申请人：——

  公开号：US9550828B2

  公开（公告）日：2017-01-24
• Biindolyls. III. Substituted 2,3'-Biindolyls from 3-Arylacetylindoles^1,2
  作者：Thomas E. Young、Michael F. Mizianty

  DOI：10.1021/jo01030a515

  日期：1964.7